and the National Policy for Rare Diseases (2021). Together, these provide a skeleton regulatory structure for rare disease research and drug development.

CDSCO and ICMR’s Role

While CDSCO oversees trial approvals and drug registrations, ICMR is instrumental in developing disease registries, ethical guidelines, and clinical trial facilitation. Some initiatives include:

• Rare Disease Registry creation for epidemiological data
• Guidance for ethical trial conduct in pediatric and terminally ill populations
• Collaboration with international rare disease research initiatives

National Policy for Rare Diseases (NPRD), 2021

The NPRD categorizes rare diseases into 3 groups, depending on therapy availability and funding needs. The policy also provides for crowd-sourced funding mechanisms and government financial support (up to ₹20 lakhs per patient for certain conditions).

Core Clinical Trial Insights

1. Study Design Challenges in Rare Diseases

Designing trials for rare diseases poses fundamental issues such as:

• Small sample size: Difficulty in achieving statistical power
• Heterogeneity: Clinical presentation varies even among patients with the same condition
• Lack of validated endpoints: No established biomarkers or surrogate endpoints

Innovative designs such as adaptive trials, basket trials, and N-of-1 trials are gaining interest, although their regulatory acceptability in India is still evolving.

2. Ethics in Vulnerable Populations

Many rare diseases present in pediatric populations. This raises complex ethical challenges:

• Informed Consent: Must be obtained from parents/guardians and include age-appropriate assent mechanisms
• Risk-Benefit Balance: Often skewed due to lack of standard therapy
• Post-Trial Access: Essential to continue treatment if drug shows benefit

ICMR’s “National Ethical Guidelines for Biomedical Research” provide useful guidance in these areas.

3. Regulatory Submissions for Rare Disease Trials

Rare disease trials must follow the same approval route under NDCTR:

• Form CT-04 submission to CDSCO
• Ethics Committee approval (preferably registered with CDSCO)
• CTRI registration mandatory before first enrollment

However, expedited reviews are possible in cases of high unmet medical need, particularly for life-threatening conditions with no standard therapy.

4. Patient Recruitment Barriers

Due to dispersed and often undiagnosed patient populations, recruitment is one of the most challenging aspects. Key strategies include:

• Partnerships with patient advocacy groups
• Use of hospital networks (AIIMS, PGI, NIMHANS) for case identification
• Leveraging the Rare Disease Registry

5. Compassionate Use and Early Access Programs

India does not have a formal expanded access program, but CDSCO permits “Compassionate Use” of investigational drugs under Rule 96 of NDCTR, especially for terminal or severely debilitating conditions.

Sponsors must apply with justification, informed consent process, safety monitoring plan, and an independent ethics committee approval.

6. Site and CRO Selection for Rare Disease Trials

Sites must have experience in handling rare disease protocols and access to specialized diagnostic and management tools. Preferred CROs are those with prior experience in low-enrollment trials and global collaboration ability.

7. Data Management and Outcome Documentation

Real-world data (RWD) and patient-reported outcomes (PROs) play a larger role in rare disease trials. EDC systems should be equipped to collect longitudinal, qualitative data as well.

Best Practices & Preventive Measures

• Early regulatory consultation to ensure alignment with CDSCO and ICMR expectations
• Use of digital recruitment platforms and patient registries to improve enrollment
• Partner with advocacy organizations for ethical and patient-centered trial design
• Plan post-trial access strategies from the outset

Scientific & Regulatory Evidence

• NDCTR 2019: India’s current regulation for new drug clinical trials, including rare conditions
• ICMR Guidelines: Ethical guidelines for pediatric and rare disease trials
• NPRD 2021: National Policy for Rare Diseases provides funding and categorization framework
• WHO and Orphanet: Global best practices adopted by Indian policymakers

Special Considerations

Pediatric Considerations: More than 50% of rare diseases affect children. Sponsors must design protocols that are age-appropriate and include pharmacokinetic adjustments.

Gene Therapy Trials: As India moves into advanced therapies, regulatory guidance for ATMPs (Advanced Therapy Medicinal Products) is under development but currently sparse.

Socioeconomic Diversity: Rare disease trials must include participants from various socioeconomic backgrounds. Government funding under NPRD helps address affordability issues.

When Sponsors Should Seek Regulatory Advice

• If trial design includes adaptive or Bayesian elements
• For pediatric rare disease protocols
• To explore compassionate use for unapproved drugs
• When applying for expedited or waived trial review

FAQs

1. Does India have an Orphan Drug Act?

No, but rare disease trials are supported under general frameworks like NDCTR and NPRD.

2. Can CDSCO fast-track rare disease trials?

Yes. For life-threatening or seriously debilitating conditions, expedited review may be available.

3. What role do patient groups play?

Patient advocacy groups are crucial for recruitment, awareness, and post-trial access negotiations.

4. Are there incentives for sponsors?

Not yet formalized. However, discussions on tax and regulatory incentives are ongoing at policy level.

5. Can foreign rare disease drugs be tested in India?

Yes, through bridging studies or direct inclusion in global trials, subject to CDSCO and Ethics Committee approvals.

Conclusion

India is making incremental yet important strides in building a regulatory and operational environment conducive to rare disease clinical trials. While gaps remain, the growing engagement from regulators, researchers, and patient groups indicates a promising path forward for inclusive and ethical research in this critical area of unmet need.